https://www.biospace.com/tolero-pharmaceuticals-to-present-at-the-34th-annual-j-p-morgan-healthcare-conference
Tolero Pharmaceuticals To Present At The 34th Annual J.P. Morgan Healthcare Conference - BioSpace
https://www.toleroh2.com/
Home | Tolero H2
Tolero H2 produces clean hydrogen
toleroh2
https://www.tolerogroup.com/
Home - TOLERO Group - Responsible and Sustainable Growth
Mar 11, 2025 - Tolero Group, a company dedicated to responsible practices, community involvement, and sustainable growth.
tolerogroupresponsiblesustainablegrowth
https://www.wsop.com/players/12337905/
VALENTE TOLERO | United States | WSOP.com
VALENTE TOLERO has won 0 bracelets and 0 rings for total earnings of $1,440. See all events where they placed in-the-money.
united statesvalentetolerowsop
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-announces-its-formation-through-merger-of-tolero-and-boston-biomedical-301086491.html
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston...
/PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc. was formed today through the merger of Tolero Pharmaceuticals, Inc., and Boston Biomedical, Inc.,...
sumitomo dainippon pharma
https://www.prnewswire.com/news-releases/tolero-pharmaceuticals-submits-investigational-new-drug-application-for-experimental-pkm2-activator-tp-1454-301061232.html
Tolero Pharmaceuticals Submits Investigational New Drug Application for Experimental PKM2 Activator...
/PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases,...
investigational new drugtoleropharmaceuticalssubmits
https://www.tolero.co/
TOLERO Marketing | Digital Marketing | Social Media Management
marketing digitalsocial mediatoleromanagement
https://www.biospace.com/tolero-pharmaceuticals-announces-first-patient-dosed-with-investigational-agent-tp-0903-in-phase-1-2-study-in-patients-with-previously-treated-chronic-lymphocytic-leukemia-andsmall-lymphocytic-lymphoma
Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-0903 in Phase...
Jun 13, 2019 - Tolero Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0903, an AXL receptor...